Health

Moderna and Merck report 42% lower melanoma recurrence risk with personalized mRNA vaccine

Moderna and Merck personalized mRNA vaccine cut melanoma recurrence or death risk by 42% in Phase 3 trial with Keytruda; RFS improved to 82.2% vs 70%.

#mRNA vaccine #Moderna #Merck #melanoma #clinical trial #cancer immunotherapy

CyberOGZ Team • October 24, 2026 • 6 views • 2 min read

Format News Brief

Read Time 2 min

Category Health

Updated Oct 24, 2026

Moderna and Merck have released Phase 3 trial results showing that their personalized mRNA cancer vaccine, when added to Keytruda, reduced the risk of recurrence or death by 42% in patients with high-risk resected melanoma.

Trial design and key findings

The INTerpath-001 study enrolled over 1,100 patients with stage IIB to IV cutaneous melanoma whose tumors had been surgically removed. Participants received either the individualized neoantigen mRNA vaccine (mRNA-4157/V940, targeting up to 34 patient-specific mutations across nine doses) plus pembrolizumab or Keytruda plus placebo.

At roughly two years of median follow-up, recurrence-free survival reached 82.2% in the combination arm versus 70% with Keytruda alone. The hazard ratio for recurrence or death was 0.58. The vaccine combination also lowered the risk of distant metastasis or death by 38%.

Why this matters for patients and clinicians

This marks the first late-stage evidence that a personalized mRNA neoantigen vaccine can improve outcomes when paired with a PD-1 inhibitor in melanoma. For patients facing high recurrence risk after surgery, the data suggest a potential new adjuvant option that builds on existing immunotherapy without adding substantial new safety signals.

The safety profile remained consistent with prior experience; adding the vaccine did not increase Keytruda-related adverse events. Overall survival data are still immature but show a favorable trend.

Practical considerations and next steps

Companies plan to engage regulators, with a possible U.S. filing and launch targeted for 2027. The vaccine is already under study in additional tumor types, which will determine whether the approach generalizes.

One open question is durability: the Phase 2 update showed a 49% risk reduction at five years, while this Phase 3 result at two years was 42%. Longer-term data and results from other cancers will clarify the ultimate clinical role.

Clinicians should watch for regulatory decisions and any expansion beyond melanoma. For now, the findings strengthen the case for continued investment in personalized mRNA cancer vaccines as a complement to checkpoint inhibitors.